Home > Financial Ratios > GLAND PHARMA
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹32,140.9 Cr -0.4% 2.9% -5.4% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹393,383.0 Cr 2.6% -5.1% -6.4% Stock Analytics
DIVIS LABORATORIES ₹162,026.0 Cr -0.5% -10.1% 21.8% Stock Analytics
CIPLA ₹126,159.0 Cr 4.7% 4.8% -4.1% Stock Analytics
TORRENT PHARMACEUTICALS ₹122,450.0 Cr 0.6% 5.2% 8.6% Stock Analytics
DR REDDYS LABORATORIES ₹104,536.0 Cr 4.3% -0.7% -11.4% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-0.4%

2.9%

-5.4%

SENSEX

-0%

-2.1%

1.1%


You may also like the below Video Courses